Sign Out
Treatment should be initiated and administered under medical supervision, e.g. in the hospital setting. Home based treatment can be recommended in exceptional cases (severe symptoms or experienced patients requiring higher doses) when a low dose rapid acting beta-agonist bronchodilator such as fenoterol hydrobromide + ipratropium bromide (Berodual) pressurised inhalation solution has been insufficient in providing relief after consultation with an experienced physician.
The treatment with the nebuliser solution in UDVs should always be started with the lowest recommended dose (1 UDV). In very severe cases two unit dose vials may be required for symptom relief. Administration should be stopped when sufficient symptom relief is achieved.
The following dosages are recommended: Adults (including elderly patients) and adolescents >12 years: Acute episodes of bronchospasm: 1 unit dose vial is sufficient for prompt symptom relief in most cases. In very severe cases two unit dose vials may be required for symptom relief.
Children ≤12 years: Because of insufficient information the general use in children ≤12 years of age is not recommended.
